R(+)-Methanandamide-Induced Apoptosis of Human Cervical Carcinoma Cells Involves A Cyclooxygenase-2-Dependent Pathway
- 268 Downloads
Cannabinoids have received renewed interest due to their antitumorigenic effects. Using human cervical carcinoma cells (HeLa), this study investigates the role of cyclooxygenase-2 (COX-2) in apoptosis elicited by the endocannabinoid analog R(+)-methanandamide (MA).
COX-2 expression was assessed by RT-PCR and Western blotting. PGE2/PGD2 levels in cell culture supernatants and DNA fragmentation were measured by ELISA.
MA led to an induction of COX-2 expression, PGD2 and PGE2 synthesis. Cells were significantly less sensitive to MA-induced apoptosis when COX-2 was suppressed by siRNA or the selective COX-2 inhibitor NS-398. COX-2 expression and apoptosis by MA was also prevented by the ceramide synthase inhibitor fumonisin B1, but not by antagonists to cannabinoid receptors and TRPV1. In line with the established role of peroxisome proliferator-activated receptor γ (PPARγ) in the proapoptotic action of PGs of the D and J series, inhibition of MA-induced apoptosis was also achieved by siRNA targeting lipocalin-type PGD synthase (L-PGDS) or PPARγ. A role of COX-2 and PPARγ in MA-induced apoptosis was confirmed in another human cervical cancer cell line (C33A) and in human lung carcinoma cells (A549).
This study demonstrates COX-2 induction and synthesis of L-PGDS-derived, PPARγ-activating PGs as a possible mechanism of apoptosis by MA.
KEY WORDSApoptosis cyclooxygenase-2 lipocalin-type prostaglandin D synthase peroxisome proliferator-activated receptor γ R(+)-methanandamide
(6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl) (4-methoxyphenyl) methanone
Cannabinoid receptor 1
Cannabinoid receptor 2
Lipocalin-type prostaglandin D synthase
Peroxisome proliferator-activated receptor γ
Reverse transcriptase-polymerase chain reaction
Transient receptor potential vanilloid-type 1
This study was supported by grants from the Deutsche Krebshilfe e.V. (Bonn, Germany), Deutsche Forschungsgemeinschaft (SFB 539 TP BI.6) and Johannes und Frieda Marohn Stiftung (Erlangen, Germany).
- 5.S. Galiegue, S. Mary, J. Marchand, D. Dussossoy, D. Carriere, P. Carayon, M. Bouaboula, D. Shire, G. L. Fur, and P. Casellas. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:54–61 (1995) doi: 10.1111/j.1432-1033.1995.tb20780.x.PubMedCrossRefGoogle Scholar
- 6.W. A. Devane, L. Hanus, A. Breuer, R. G. Pertwee, L. A. Sevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1946–1949 (1992) doi: 10.1126/science.1470919.PubMedCrossRefGoogle Scholar
- 8.R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligunsky, N. E. Kaninski, A. R. Schatz, A. Gopher, S. Almog, B. R. Martin, D. R. Compton, R. G. Pertwee, G. Griffin, M. Bayewitch, J. Barg, and Z. Vogel. Identification of an endogenous 2-monoglyceride, present in canine-gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:83–90 (1995) doi: 10.1016/0006-2952(95)00109-D.PubMedCrossRefGoogle Scholar
- 12.A. Ligresti, T. Bisogno, I. Matias, L. D. Petrocellis, M. Cascio, V. Cosenza, G. D’argenio, G. Scaglione, M. Bifulco, I. Sorrentini, and V. D. Marzo. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 125:677–687 (2003) doi: 10.1016/S0016-5085(03)00881-3.PubMedCrossRefGoogle Scholar
- 14.V. DiMarzo, T. Bisogno, L. De Petrocellis, D. Melck, and B. R. Martin. Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. Curr. Med. Chem. 6:721–744 (1999).Google Scholar
- 15.V. DiMarzo, C. S. Breivogel, Q. Tao, D. T. Bridgen, R. K. Razdan, A. M. Zimmer, A. Zimmer, and B. R. Martin. Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice: evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 75:2434–2444 (2000) doi: 10.1046/j.1471-4159.2000.0752434.x.CrossRefGoogle Scholar
- 27.Y. E. Dommels, M. M. Haring, N. G. Keestra, G. M. Alink, P. J. van Bladeren, and B. van Ommen. The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE2 synthesis and cytotoxicity in human colorectal carcinoma cell lines. Carcinogenesis. 24:385–392 (2003) doi: 10.1093/carcin/24.3.385.PubMedCrossRefGoogle Scholar
- 31.J. Kim, P. Yang, M. Suraokar, A. L. Sabichi, N. D. Llansa, G. Mendoza, V. Subbarayan, C. J. Logothetis, R. A. Newman, S. M. Lippman, and D. G. Menter. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res. 65:6189–6198 (2005) doi: 10.1158/0008-5472.CAN-04-4439.PubMedCrossRefGoogle Scholar
- 33.L. Mestre, F. Correa, F. Docagne, D. Clemente, and C. Guaza. The synthetic cannabinoid WIN 55,212–2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler’s virus infection. Biochem. Pharmacol. 72:869–880 (2006) doi: 10.1016/j.bcp.2006.06.037.PubMedCrossRefGoogle Scholar
- 35.K. Subbaramaiah, W. Chung, and A. Dannenberg. Ceramide regulates the transcription of cyclooxygenase-2. evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. J. Biol. Chem. 273:32943–32949 (1998) doi: 10.1074/jbc.273.49.32943.PubMedCrossRefGoogle Scholar
- 40.B. Hinz, K. Brune, and A. Pahl. Cyclooxygenase-2 expression in lipopolysaccharide-stimulated human monocytes is modulated by cyclic AMP, prostaglandin E2, and nonsteroidal anti-inflammatory drugs. Biochem. Biophys. Res. Commun. 278:790–6 (2000) doi: 10.1006/bbrc.2000.3885.PubMedCrossRefGoogle Scholar
- 42.S. Rosch, R. Ramer, K. Brune, and B. Hinz. Prostaglandin E2 induces cyclooxygenase-2 expression in human non-pigmented ciliary epithelial cells through activation of p38 and p42/44 mitogen-activated protein kinases. Biochem. Biophys. Res. Commun. 338:1171–1178 (2005) doi: 10.1016/j.bbrc.2005.10.051.PubMedCrossRefGoogle Scholar
- 43.L. Lalier, P. F. Cartron, F. Pedelaborde, C. Olivier, D. Loussouarn, S. A. Martin, K. Meflah, J. Menanteau, and F. M. Vallette. Increase in PGE2 biosynthesis induces a Bax dependent apoptosis correlated to patients’ survival in glioblastoma multiforme. Oncogene. 26:4999–5009 (2007) doi: 10.1038/sj.onc.1210303.PubMedCrossRefGoogle Scholar
- 51.C. E. Rockwell, N. T. Snider, J. T. Thompson, J. P. Vanden Heuvel, and N. E. Kaminski. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor γ independently of cannabinoid receptors 1 and 2. Mol. Pharmacol. 70:101–111 (2006).PubMedGoogle Scholar